1440-1843/asset/RESP_left.gif?v=1&s=a110bec2019e1353a37e9b3af15908c01a36bc31)
1440-1843/asset/RESP_right.gif?v=1&s=2996c5a131272e16b9e97c7ece43b33e2548b8e2)
Aerosolized vancomycin for the treatment of MRSA after lung transplantation
Article first published online: 5 NOV 2009
DOI: 10.1111/j.1440-1843.2009.01647.x
© 2009 The Authors. Journal compilation © 2009 Asian Pacific Society of Respirology
Additional Information
How to Cite
HAYES JR, D., MURPHY, B. S., MULLETT, T. W. and FEOLA, D. J. (2010), Aerosolized vancomycin for the treatment of MRSA after lung transplantation. Respirology, 15: 184–186. doi: 10.1111/j.1440-1843.2009.01647.x
Publication History
- Issue published online: 27 DEC 2009
- Article first published online: 5 NOV 2009
- Received 13 October 2008; invited to revise 1 November 2008, 18 November 2008, 25 November 2008; revised 14 November 2008, 21 November 2008, 26 November 2008; Accepted 27 November 2008 (Associate Editor: David Hui)
- Abstract
- Article
- References
- Cited By
Keywords:
- aerosolized;
- cystic fibrosis;
- lung transplantation;
- methicillin-resistant Staphylococcus aureus;
- vancomycin
ABSTRACT
Lung transplantation is the only life-prolonging therapy available for cystic fibrosis (CF) patients with end-stage lung disease. The presence of pathogens in the airways of CF patients prior to transplantation is the major risk factor for infection in the post-transplantation period, with methicillin-resistant Staphylococcus aureus (MRSA) having a growing impact. Aerosolized vancomycin has been used successfully in the treatment of MRSA in the CF population but its use after lung transplantation has not been previously reported. We report the case of a lung transplant recipient who was successfully treated for MRSA infection with aerosolized vancomycin.